Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 34
- Registration Number
- NCT04315233
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04256941
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ribociclib and Spartalizumab in R/M HNSCC
- Conditions
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT04213404
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 455
- Registration Number
- NCT04116541
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04000529
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer
- Conditions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 78
- Registration Number
- NCT03956654
- Locations
- 🇧🇪
UZ Gasthuisberg Leuven, Leuven, Belgium
FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Target Recruit Count
- 116
- Registration Number
- NCT03944434
- Locations
- 🇮🇹
Hospital of Prato, Prato, Please select:, Italy
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 25
- Registration Number
- NCT03905343
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Belgium
🇧🇪Jessa Ziekenhuis, Hasselt, Belgium
🇨🇭Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT03839823
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
- Conditions
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 27
- Registration Number
- NCT03834740
- Locations
- 🇺🇸
HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Chandler Regional Medical Center, Chandler, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.